Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

15.69 +0.30 (+1.95%)
Streaming Delayed Price Updated: 10:33 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neogenomics Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) rose 40.1% to $21.00 in pre-market trading following announcement of collaboration with Sanofi (NASDAQ: SNY). Guardforce AI Co.,... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start another busy day of trading with another breakdown of the biggest pre-market stock movers on Tuesday! 
Via InvestorPlace
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in NeoGenomics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Recap: NeoGenomics Q4 Earnings
NeoGenomics (NASDAQ:NEO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Where NeoGenomics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on NeoGenomics (NASDAQ: 
Via Benzinga
SHAREHOLDER ALERT - Labaton Sucharow Investigating NeoGenomics Inc. - NEO
From Labaton Sucharow LLP
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers NexImmune (NASDAQ:NEXI) stock moved upwards by 8.3% to $3.51 during Monday's after-market session. This security traded at a volume of 109.1K shares come close, making up 76.6% of its average... 
Via Benzinga
NeoGenomics Announces CEO Departure and Initiates CEO Search
Board Appoints Executive Chair and Interim Office of the CEO Anticipates First Quarter Results Below Guidance and Withdraws 2022 Guidance FT. MYERS, FL / ACCESSWIRE / March 28, 2022 / NeoGenomics, Inc.... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
Study further highlights potential of RaDaR to stratify patients and improve treatment outcomes FT. MYERS, FL / ACCESSWIRE / March 17, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Earnings Perspective: Return On Capital Employed
NeoGenomics (NASDAQ:NEO) brought in sales totaling $125.73 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 105.22%, resulting in a loss... 
Via Benzinga
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
FT MYERS, FL / ACCESSWIRE / March 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
10 Biggest Price Target Changes For Thursday
SVB Leerink lowered Guardant Health, Inc. (NASDAQ: GH) price target from $170 to $140. Guardant Health shares dropped 5.7% to $56.22 in pre-market trading. 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021
Recent Highlights: - Full year 2021 consolidated revenue increased 9% year-over-year; excluding COVID-19 PCR testing revenue, consolidated revenue increased 16% - Fourth quarter consolidated revenue... 
From NeoGenomics, Inc.
Via AccessWire
Exposures COVID-19
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
Dash, Amp Among Top Crypto Movers In 24H
After pulling data from Benzinga Pro the following is the list of top crypto gainers an... 
Via Benzinga
Celsius Network, NEO Among Top Crypto Movers In 24H
According to Benzinga Pro, the following are the crypto gainers and losers at the time ... 
Via Benzinga
NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer
FT. MYERS, FL / ACCESSWIRE / February 14, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
RaDaR demonstrated 100% specificity in patients with no recurrence and 100% sensitivity in patients with clinical recurrence FT MYERS, FL / ACCESSWIRE / February 11, 2022 / NeoGenomics, Inc.... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences
FT. MYERS, FL / ACCESSWIRE / February 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022
FT MYERS, FL / ACCESSWIRE / February 2, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
The partnership makes it possible for patients with specific biomarkers to get early support FT. MYERS, FL / ACCESSWIRE / January 24, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 10, 2021 – USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as... 
Via FinancialNewsMedia
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXT... 
Via Benzinga
NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary
FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE: 
Via Benzinga
NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers
FT. MYERS, FL / ACCESSWIRE / December 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.